Chemokine receptor CXCR4 expression and prognosis in patients with metastatic prostate cancer

Cancer Science

Volumn 99, Issue 3, 2008, Pages 539-542

  Akashi, Takuya ^a,b   Koizumi, Keiichi ^b   Tsuneyama, Koichi ^a   Saiki, Ikuo ^a,b   Takano, Yasuo ^a   Fuse, Hideki ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CHLORMADINONE ACETATE; FOSFESTROL;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEEDLE BIOPSY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION;

EID: 38949185673     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00712.x     Document Type: Article

References (27)

1. Zlotnik A, Yoshie O. Chemokines. a new classification system and their role in immunity. Immunity 2000; 12: 121-7.
2. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. Lymphocyte trafficking and regional immunity. Adv Immunol 1999; 72: 209-53.
3. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-7.
4. Muller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
5. Spano JP, Andre F, Morat L, Sabatier L et al. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: Pattern of expression and correlation with outcome. Ann Oncol 2004; 15: 613-17.
6. Scala S, Ottaiano A, Ascierto PA et al. Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 2005; 11: 1835-41.
7. Koishi K, Yoshikawa R, Tsujimura T et al. Persistent CXCR4 expression after preoperative chemoradiotherapy predicts early recurrence and poor prognosis in esophageal cancer. World J Gastroenterol 2006; 12: 7585-90.
8. Jiang YP, Wu XH, Shi B, Wu WX, Yin GR. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: An independent prognostic factor for tumor progression. Gynecol Oncol 2006; 103: 226-33.
9. Oda Y, Yamamoto H, Tamiya S et al. CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: Analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 2006; 19: 738-45.
10. Gleason DF. Histologic grading of prostate cancer: A perspective. Hum Pathol 1992; 23: 273-9.
11. Soloway MS. The important prognostic factors in advanced prostate cancer. Cancer 1990; 66: 1017-21.
12. Payne AS, Cornelius LA. The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol 2002; 118: 915-22.
13. Scotton CJ, Wilson JL, Scott K et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002; 62: 5930-8.
14. Kijima T, Maulik G, Ma PC et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res 2002; 62: 6304-11.
15. Sun YX, Wang J, Shelburne CE et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in.vivo. J Cell Biochem 2003; 89: 462-73.
16. Geminder H, Sagi-Assif O, Goldberg L et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001; 167: 4747-57.
17. Catalona WJ, Smith DS. Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 1998; 160: 2428-34.
18. Mochizuki H, Matsubara A, Teishima J et al. Interaction of ligand-receptor system between stromal-cell-derived factor-1 and CXC chemokine receptor 4 in human prostate cancer: A possible predictor of metastasis. Biochem Biophys Res Commun 2004; 30: 656-63.
19. Hart CA, Brown M, Bagley S, Sharrard M, Clarke NW. Invasive characteristics of human prostatic epithelial cells: Understanding the metastatic process. Br J Cancer 2005; 92: 503-12.
20. Salvucci O, Bouchard A, Baccarelli A et al. The role of CXCR4 receptor expression in breast cancer: A large tissue microarray study. Breast Cancer Res Treat 2006; 97: 275-83.
21. Darash-Yanaha M, Pikarsky E, Abramovitch R et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004; 18: 1240-2.
22. Murakami T, Maki W, Cardones AR et al. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res 2002; 62: 7328-34.
23. De Clercq E. Potential clinical applications of the CXCR4 antagonist Bicyclam AMD3100. Mini Rev Med Chem 2005; 5: 805-24.
24. Rubin JB, Kung AL, Klein RS et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 2003; 100: 13.513-18.
25. Tamamura H, Hori A, Kanzaki N et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 2003; 28: 79-83.
26. Smith MC, Luker KE, Garbow JR et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 2004; 64: 8604-12.
27. Takenaga M, Tamamura H, Hiramatsu K et al. A single treatment with microcapsules containing a CXCR4 antagonist suppresses pulmonary metastasis of murine melanoma. Biochem Biophys Res Commun 2004; 320: 226-32.